{"entity":{"id":"nct03777982","kind":"trial","name":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","aka":[],"tldr":"A phase 3 trial of Prednisone and Apalutamide and Abiraterone acetate in Prostate cancer, run by Dana-Farber Cancer Institute, recorded as terminated on the registry.","summary":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT is a phase 3 interventional study registered as NCT03777982 by Dana-Farber Cancer Institute, with 12 participants recorded, started 2020-04-20 and due to reach its primary completion in 2024-02-13. Interventions recorded: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist. Conditions recorded: Prostate Cancer.\n\nLinked to the idea \"Prescribe a quarter dose of abiraterone with breakfast\" because the registry names Prednisone and Apalutamide and Abiraterone acetate among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03777982","url":"https://clinicaltrials.gov/study/NCT03777982"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["prednisone","apalutamide","abiraterone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03777982","phase":"3","setting":"A Randomized Phase III Study - Conventional Androgen Deprivation Therapy With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and Androgen Deprivation Therapy","sponsor":"Dana-Farber Cancer Institute","participation":[{"nct":"NCT03777982","source":"https://clinicaltrials.gov/study/NCT03777982","fetchedAt":"2026-10-07T16:53:08.563Z","studySha256":"4546ce45ae22db6edaf4b1ff4fa13fe3192a5e2754931d9ea12ad5a9f00222d6","overallStatus":"TERMINATED","lastUpdatePosted":"2024-09-19","whyStopped":"PI is terminating the study due to slow/low accrual","leadSponsor":"Dana-Farber Cancer Institute","collaboratorCount":1,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":12,"enrolmentType":"ACTUAL","siteCount":5,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2020-04-20","startedType":"actual","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03777982/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"idea":[{"id":"idea-cost-low-dose-abiraterone-food","kind":"idea","name":"Prescribe a quarter dose of abiraterone with breakfast","route":"/ideas/idea-cost-low-dose-abiraterone-food/"}]}}